Sep 22, 2026 08:30AM
Sep 22, 2026 08:30AM
Aug 14, 2026 08:32AM
Aug 6, 2026 08:31AM
Aug 6, 2026 08:30AM
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Jun 15, 2026 04:30PM
Jun 9, 2026 08:31AM
Jun 9, 2026 08:30AM
May 12, 2026 07:30AM
May 12, 2026 07:30AM
May 8, 2026 07:30AM
May 8, 2026 07:30AM Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Apr 22, 2026 08:30AM
Apr 22, 2026 08:30AM
Feb 12, 2026 04:30PM
Dec 17, 2025 08:30AM
Dec 17, 2025 08:30AM
Nov 17, 2025 09:26AM
Nov 13, 2025 04:30PM Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
Nov 3, 2025 11:04AM
Nov 3, 2025 08:30AM
Oct 29, 2025 08:30AM
Oct 29, 2025 08:30AM
Oct 29, 2025 08:30AM
Aug 7, 2025 04:30PM
Jun 25, 2025 08:36AM VistaGen Therapeutics (VTGN) names Elissa Cote Chief Corporate Development Officer
Jun 25, 2025 08:30AM
Jun 17, 2025 04:30PM
Jun 2, 2025 08:31AM
Jun 2, 2025 08:30AM
Feb 13, 2025 04:30PM
Feb 5, 2025 08:32AM
Feb 5, 2025 08:30AM Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Jan 10, 2025 08:30AM
Nov 7, 2024 04:20PM
Nov 5, 2024 08:30AM
Sep 23, 2024 08:31AM
Sep 23, 2024 08:30AM
Aug 13, 2024 04:21PM
Jun 11, 2024 04:20PM Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
May 23, 2024 08:30AM
Apr 9, 2024 08:30AM
Apr 1, 2024 08:30AM
Apr 1, 2024 08:30AM
Feb 13, 2024 04:20PM
Dec 27, 2023 08:30AM
Dec 27, 2023 08:30AM Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
Dec 7, 2023 09:22AM

335,960 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All